¼¼Å¬·Ï½º¾×(½ÃŬ·ÎÇǷϽº¿Ã¾Æ¹Î) CECLROX SOL.[Ciclopirox Olamine]
ÀϹÝÀǾàǰ | ºñ±Þ¿©
¾Ë¸²:
µå·°ÀÎÆ÷¿¡¼´Â ÀǾàǰ ÀÎÅÍ³Ý ÆÇ¸Å¸¦ ÇÏÁö ¾Ê½À´Ï´Ù.
Àü¹®/ÀϹÝ
ÀϹÝ
ÀÌ ¾àÀº Ȳ»öÀÇ Á¡¼ºÀÌ ÀÖ´Â ¾×Á¦ÀÌ´Ù.
Á¦Á¶È¸»ç
(ÁÖ)Çѱ¹ÆÄ¸¶
ÆÇ¸Åȸ»ç
(ÁÖ)Çѱ¹ÆÄ¸¶
Çã°¡Á¤º¸
ÃëÇÏ
(2020.02.19)
BIT ¾àÈ¿ºÐ·ù
¿Ü¿ë Ç×Áø±ÕÁ¦ (Antifungals : Skin & Mucous Membrane)
º¹ÁöºÎºÐ·ù
265[±â»ý¼º ÇǺÎÁúȯ¿ëÁ¦ ]
û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå
653001030[A12654181]\0 ¿ø/1g(2010.11.01) (ÇöÀç¾à°¡) \44 ¿ø/1g(2007.10.01)(º¯°æÀü¾à°¡)
ATCÄÚµå
Ciclopirox / D01AE14
NDCÄÚµå
[Proprietary Name Search _ ƯÇãµî·Ï¸í,»óÇ¥¸íÀ¸·Î °Ë»ö]
[Active Ingredient Search _ ÁÖ¼ººÐÀ¸·Î °Ë»ö]
[NDC Number Search _ NDCÄÚµå·Î °Ë»ö]
¼ººÐ / ÇÔ·®
[½ÉÆò¿ø ÁÖ¼ººÐÄÚµå ±âÁØ ¼ººÐÇÔ·®Á¤º¸ Á¶È¸]
÷°¡Á¦
±¸¿¬»ê ,
ºÎÆ¿·»±Û¶óÀÌÄÝ ,
¼Òµã¶ó¿ì¸±¼³ÆäÀÌÆ®¾× ,
¿Ã·¹ÀϾËÄÚ¿Ã ,
Àλê¼ö¼Ò³ªÆ®·ý ,
Á¤Á¦¼ö ,
Á¶ÇÕÇâ·á(»ç°úÇâHF-30630) ,
ÄÚÄ«¸¶À̵µÇÁ·ÎÇʺ£Å¸ÀÎ ,
ÄÚÄ«¸¶À̵åµðÀÌ¿¡ÀÌ ,
Æú¸®¼Ò¸£º£ÀÌÆ®80 ,
Æú¸®ÄõÅÍ´½-10 ,
ÇÁ·ÎÇÊ·»±Û¸®ÄÝ
À¯·áȸ¿ø °áÀç½Ã ¿¡´Â º¸´Ù ´Ù¾çÇÑ ¾à¹°Á¤º¸ ¸¦
ÀÌ¿ë ÇÏ½Ç ¼ö ÀÖ½À´Ï´Ù.
À¯·áÁ¤º¸¸ñ·Ï Àº Àü¹®È¸¿ø À¸·Î
·Î±×ÀÎ ÇϽøé È®ÀÎ °¡´ÉÇÕ´Ï´Ù.
Çã°¡Á¤º¸
Ç׸ñ
³»¿ë
û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå »óÇѱݾ×
653001030[A12654181]
[º¸ÇèÄڵ忡 µû¸¥ ¾àǰ±âº»Á¤º¸ Á÷Á¢Á¶È¸]
\0 ¿ø/1g(2010.11.01) (ÇöÀç¾à°¡)
\44 ¿ø/1g(2007.10.01)(º¯°æÀü¾à°¡)
[»óº´ÄÚµåÁ¶È¸]
[Áúº´ÄÚµåÁý ´Ù¿î·Îµå]
[¿ì¸®Áý°Ç°ÁÖÄ¡ÀÇ ¹Ù·Î°¡±â]
ºü¸¥Á¶È¸
Á¦Ç°¼º»ó
ÀÌ ¾àÀº Ȳ»öÀÇ Á¡¼ºÀÌ ÀÖ´Â ¾×Á¦ÀÌ´Ù.
[Á¦ÇüÁ¤º¸ È®ÀÎ]
ÁÖ¼ººÐÄÚµå
132804CLQ
[µ¿ÀÏÇÑ ÁÖ¼ººÐÄڵ带 °¡Áø ¿À¸®Áö³¯ ¶Ç´Â Á¦³×¸¯ ÀǾàǰ Á¶È¸]
´ëÇ¥ÄÚµå
8806530010302
º¸°ü¹æ¹ý
±â¹Ð, Â÷±¤¿ë±â 25¡ÉÀÌÇÏ º¸°ü
¾à¸®ÀÛ¿ë
[Á¶È¸]
È¿´ÉÈ¿°ú
[ÀûÀÀÁõ º° °Ë»ö]
Áö·ç¼ºÇǺο°
¿ë¹ý¿ë·®
* Àý´ë ÀÓÀǺ¹¿ëÇÏÁö ¸¶½Ã°í ¹Ýµå½Ã ÀÇ»ç ¶Ç´Â ¾à»ç¿Í »ó´ãÇϽñ⠹ٶø´Ï´Ù.
[󹿾à¾î]
¸Ó¸®¸¦ ¹°·Î Àû½Å ÈÄ °ÅǰÀÌ ³¯ Á¤µµÀÇ ÃæºÐÇÑ ¾çÀ» Àû¿ëÇÏ¿© ¼Õ°¡¶ô ³¡À¸·Î ÃæºÐÈ÷ ¸¶»çÁöÇÑ´Ù. 3-5ºÐ ÈÄ ¸ð¹ßÀ» ¹°·Î ¿©·¯ ¹ø Çó±¸¾î ¿ÏÀüÈ÷ ¾Ä¾î³½´Ù.
ÀÌ ¾àÀº ÀÏÁÖÀÏ¿¡ 2-3ȸ ¶Ç´Â µÎÇÇ Áúȯ Ä¡·á½Ã ÇÊ¿äÇÒ ¶§¸¶´Ù »ç¿ëÇÑ´Ù
±Ý±â
ÀÌ ¾à ¶Ç´Â ÀÌ ¾àÀÇ ¼ººÐ¿¡ °ú¹ÎÁõÀÌ Àִ ȯÀÚ
½ÅÁßÅõ¿©
´ÙÀ½°ú °°Àº »ç¶÷Àº ÀÌ ¾àÀ» »ç¿ëÇϱâ Àü¿¡ ÀÇ»ç, ¾à»ç¿Í »óÀÇÇÒ °Í
1) ÀÌ ¾à ¶Ç´Â ÀÌ ¾àÀÇ ¼ººÐ¿¡ ¾Ë·¹¸£±â Áõ»ó[¿¹¸¦ µé¸é ¹ßÁø, ¹ßÀû(ÃæÇ÷µÇ¾î ºÓ¾îÁü), °¡·Á¿ò, ¿Ì µî¿¡ ÀÇÇÑ ÇǺο° µî]ÀÌ Àִ ȯÀÚ
2) º»ÀÎ ¶Ç´Â °¡Á·ÀÌ ¾Ë·¹¸£±â üÁúÀΠȯÀÚ
3) ȯºÎ(Áúȯ ºÎÀ§)°¡ ¾È¸é(¾ó±¼)À̰ųª ±¤¹üÀ§ÇÑ È¯ÀÚ
4) ȯºÎ(Áúȯ ºÎÀ§)°¡ ȳó(°òÀ½)¼ºÀΠȯÀÚ
5) ÀӽźΠ¹× ¼öÀ¯ºÎ
6) 12¼¼ ¹Ì¸¸ÀÇ ¼Ò¾Æ
7) ÀÇ»çÀÇ Ä¡·á¸¦ ¹Þ°í Àִ ȯÀÚ
ÀÌ»ó¹ÝÀÀ
´ÙÀ½°ú °°Àº °æ¿ì ÀÌ ¾àÀÇ »ç¿ëÀ» Áï°¢ ÁßÁöÇϰí ÀÇ»ç, ¾à»ç¿Í »óÀÇÇÒ °Í. »ó´ã ½Ã °¡´ÉÇÑ ÇÑ ÀÌ Ã·ºÎ¹®¼¸¦ ¼ÒÁöÇÒ °Í
1) ÇǺΠÀÚ±Ø
2) ¹Ì¶õ(ÇǺÎÀÚ±Ø)
ÀÌ»ó¹ÝÀÀ
1) ÀÓ»ó½ÃÇè
¨ç ÇǺΠ¹× ÇÇÇÏÁ¶Á÷ ÀÌ»ó¹ÝÀÀ: °¡·Á¿òÁõ, ÀÛ¿°¨(Ȳö°¨), È«¹Ý*¹× Àû¿ëºÎÀ§ ¹ßÁø*°ú °°Àº Àû¿ëºÎÀ§ ÀÚ±ØÀÌ ÈçÇϰÔ(¡Ã1/100 À̰í <1/10) ¹ß»ýÇÑ´Ù.
2) ½ÃÆÇ ÈÄ Á¶»ç °á°ú
¨ç ¸é¿ª°è ÀÌ»ó¹ÝÀÀ: Àû¿ëºÎÀ§ °ú¹ÎÁõÀÌ µå¹°°Ô(¡Ã1/10,000 À̰í < 1/1,000) ¹ß»ýÇÏ¿´´Ù.
¨è ÇǺΠ¹× ÇÇÇÏÁ¶Á÷ ÀÌ»ó¹ÝÀÀ: ÇǺιڸ®*, ½ÀÁø, Å»¸ðÁõ*, ¸Ó¸®Ä«¶ô º¯»ö ¹× ¸ð¹ßÀÇ Áú°¨ º¯È*°¡ µå¹°°Ô(¡Ã1/10,000 À̰í < 1/1,000) ¹ß»ýÇÏ¿´´Ù.
* Ç¥½ÃÀÇ ¹ÝÀÀµéÀº ±âÀúÁúȯÀÇ Áõ»óµéÀ̱⵵ ÇϹǷΠ±âÀúÁúȯ Áõ»óÀÌ ¾Çȵʿ¡ µû¶ó ÀÌ·¯ÇÑ ÀÌ»ó¹ÝÀÀµéÀÌ ³ªÅ¸³ª±âµµ ÇÒ °ÍÀÌ¶ó ¿¹ÃøµÈ´Ù.
ÀϹÝÀû ÁÖÀÇ
1) ÀÌ ¾àÀº µÎÇÇ¿Í ÀÎÁ¢ºÎÀ§¿¡ ¿Ü¿ëÀ¸·Î¸¸ »ç¿ëÇÑ´Ù.
2) Á¤ÇØÁø ¿ë¹ý¤ý¿ë·®À» Àß Áö۰í, ´ÙÀ½ ºÎÀ§¿¡´Â Åõ¿©ÇÏÁö ¸» °Í. ´ÙÀ½ ºÎÀ§¿¡ µé ¾î °¬À» °æ¿ì¿¡´Â ÃæºÐÇÑ ¾çÀÇ ¹°·Î ¿ÏÀüÈ÷ ¾Ä¾î³»°í ÀÚ±ØÀÌ °è¼ÓµÉ °æ¿ì ÀÇ»ç, ¾à»ç¿Í »óÀÇÇÒ °Í.
¨ç ´« ¶Ç´Â ´«ÁÖÀ§, Á¡¸·[¿¹¸¦ µé¸é ±¸°, ºñ°(ÄÚ¾È), Áú µî], À½ºÎ, ¿ÜÀ½ºÎ µî
¨è ½ÀÁø
¨é ½ÀÀ±, ¹Ì¶õ(Áø¹«¸§), ±Õ¿ ¶Ç´Â ¿Ü»ó(»óó)ÀÌ ½ÉÇÑ È¯ºÎ(Áúȯ ºÎÀ§)
3) ȯºÎ(Áúȯ ºÎÀ§) ¶Ç´Â ±× ÁÖÀ§°¡ ´õ·¯¿î °æ¿ì¿¡´Â ¹Ù·Î »ç¿ëÇÏÁö ¾Ê´Â´Ù.
4) 2ÁÖ Á¤µµ Åõ¿© ÈÄ¿¡µµ Áõ»óÀÇ °³¼±ÀÌ º¸ÀÌÁö ¾ÊÀ» °æ¿ì¿¡´Â Åõ¿©¸¦ ÁßÁöÇÏ°í ¾à»ç ¶Ç´Â ÀÇ»ç¿Í »óÀÇÇÑ´Ù.
5) µå¹°°Ô´Â ÁÖ·Î ÈÇÐÀûÀ¸·Î ¼Õ»óµÈ ¸Ó¸®Ä«¶ô(¿¹¸¦ µé¾î ¿°»öÀ¸·Î ÀÎÇÑ), ȸ»ö ¶Ç´Â Èò ¸Ó¸®Ä«¶ôÀÇ È¯Àڵ鿡°Ô¼ ¸Ó¸®Ä«¶ô Å»»öÀÌ °üÂûµÇ±âµµ ÇÏ¿´´Ù.
ÀӺο¡ ´ëÇÑ Åõ¿©
[ÀӺαݱ⠼ººÐ Á¶È¸]
¨ç ÀÌ ¾àÀ» µ¿¹°¿¡°Ô °æ±¸ ¶Ç´Â ÇÇÇÏ Åõ¿©ÇÑ ½ÃÇè¿¡¼ °¡ÀÓ(ÀӽŰ¡´É¼º)¿¡ ´ëÇÑ Àå¾Ö°¡ ³ªÅ¸³ªÁö ¾Ê¾Ò´Ù.
¨è ÀӽźÎ
ÀӺο¡ ´ëÇÑ ÀÌ ¾àÀÇ ¾ÈÀü¼ºÀº È®¸³µÇÁö ¾Ê¾Ò´Ù. ÇÏÁö¸¸ ÀÌ ¾àÀ» µ¿¹°¿¡°Ô °æ±¸ ¶Ç´Â ÇÇÇÏ Åõ¿©ÇÑ ½ÃÇè¿¡¼ ¹ß»ýµ¶¼ºÀÌ ³ªÅ¸³ªÁö ¾Ê¾Ò´Ù.
¼öÀ¯ºÎ¿¡ ´ëÇÑ Åõ¿©
ÀÌ ¾àÀÌ ¸ðÀ¯¿¡ ÀÌÇàµÇ´ÂÁö´Â ¾Ë·ÁÁ® ÀÖÁö ¾Ê´Ù.
ÀÌ ¾àÀ» »ç¿ëÇÏ´Â ¼öÀ¯ºÎ´Â ¼öÀ¯ Àü¿¡ °¡½¿¿¡ ³²Àº ÀÌ ¾àÀÇ ÀÜ¿©¹°À» ¿ÏÀüÈ÷ ¾Ä¾î¾ß ÇÑ´Ù.
¼Ò¾Æ¿¡ ´ëÇÑ Åõ¿©
¼Ò¾Æ¿¡°Ô »ç¿ëÇÒ °æ¿ì¿¡´Â º¸È£ÀÚÀÇ Áöµµ¤ý°¨µ¶ ÇÏ¿¡ »ç¿ëÇÑ´Ù.
°ú·®Åõ¿© ¹× óġ
°ú·® Åõ¿© ½Ã ÀÇ·á±â°üÀÌ ±ÇÀåÇÏ´Â ¹æ¹ýÀ» µû¸¥´Ù. ÀÌ ¾àÀ» »ç°í·Î »ïÄ×À» ¶§ Ưº°ÇÑ Ä¡·á¹æ¹ýÀº ¾ø´Ù. ¸¸¾à »ç°í·Î »ïÄ×´Ù¸é ȯÀÚ´Â ÇÊ¿ä½Ã¸¶´Ù ÀûÀýÇÑ °üÂû°ú Ä¡·á¸¦ ¹Þ¾Æ¾ß ÇÑ´Ù.
º¸°ü ¹× Ãë±Þ»óÀÇ ÁÖÀÇ
1) ¼Ò¾ÆÀÇ ¼ÕÀÌ ´êÁö ¾Ê´Â °÷¿¡ º¸°üÇÒ °Í.
2) Á÷»çÀϱ¤À» ÇÇÇÏ°í µÉ ¼ö ÀÖÀ¸¸é ½À±â°¡ Àû°í ¼´ÃÇÑ °÷¿¡ º¸°üÇÑ´Ù.
3) ÀǾàǰÀ» ¿ø·¡ ¿ë±â¿¡ ²¨³»¾î ´Ù¸¥ ¿ë±â¿¡ º¸°üÇÏ´Â °ÍÀº ÀǾàǰ ¿À¿ë¿¡ ÀÇÇÑ »ç °í ¹ß»ýÀ̳ª ÀǾàǰ ǰÁúÀúÇÏÀÇ ¿øÀÎÀÌ µÉ ¼ö ÀÖÀ¸¹Ç·Î ¿ø·¡ÀÇ ¿ë±â¿¡ ³Ö°í ²À ´Ý¾Æ º¸°üÇÒ °Í.
4) ȱ⿡ °¡±îÀÌ ÇÏÁö ¾Ê´Â´Ù.
Á¤º¸¿ä¾à
µå·°ÀÎÆ÷ ÀǾàǰ ¿ä¾à/»ó¼¼Á¤º¸
ÄÚµå ¹× ºÐ·ùÁ¤º¸
Á¦Ç°Á¤º¸
º¹¾àÁ¤º¸
Ç׸ñ
³»¿ë
LACTmed ¹Ù·Î°¡±â
[¹Ù·Î°¡±â]
¾à¸®ÀÛ¿ë
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
Ãà¾àº¹¾àÁöµµ
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
º¹¾àÁöµµ
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
ÀӺο¡´ëÇÑÅõ¿©
*
ÀüüÀӽŠ±â°£º°·Î ¿©·¯µî±ÞÀÌ Á¸ÀçÇÒ ¼ö ÀÖÀ¸¸ç °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ º¸¿©Áý´Ï´Ù. ´Ü, º¹ÇÕÁ¦ÀÇ °æ¿ì ¸ðµç º¹ÇÕÁ¦¼ººÐ¿¡ ´ëÇÑ ÀÓºÎÅõ¿©µî±ÞÀÌ Ç¥½ÃµÈ°ÍÀº Àý´ë ¾Æ´Ï¸ç Ç¥½ÃµÈ°ÍÁß¿¡ °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ ³ªÅ¸³³´Ï´Ù.
 
FDA : Bµî±Þ
*
»ó±â ÀÓºÎÅõ¿©¿¡ ´ëÇÑ Á¤º¸´Â Àü»êó¸® µÇ¸é¼ ÀÔ·Â ¿À·ù °¡´É¼ºÀÌ Á¸ÀçÇÕ´Ï´Ù. ¿À·ù °¡´É¼ºÀ» ÃÖ¼ÒÈÇϱâ À§ÇÏ¿© ¸¹Àº ³ë·ÂÀ» ±â¿ïÀ̰í ÀÖÀ¸³ª, ±× Á¤È®¼º¿¡ ´ëÇÏ¿© È®½ÅÀ» µå¸± ¼ö ¾ø½À´Ï´Ù. ÀÌ¿¡ ´ëÇØ ȸ»ç´Â Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù.
*
¹Ýµå½Ã °ø½Å·Â ÀÖ´Â ¹®ÇåÀ» ´Ù½Ã Çѹø Âü°í ÇϽñ⠹ٶó¸ç ÀÇ»ç ¶Ç´Â ¾à»çÀÇ ÆÇ´Ü¿¡ µû¶ó Åõ¿©¿©ºÎ°¡ °áÁ¤µÇ¾î¾ß ÇÕ´Ï´Ù.
Pharmacokinetics
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
º´¿ë±Ý±â ¹× ¿¬·É´ë±Ý±â ±Ù°ÅÁ¶È¸
[º´¿ë±Ý±â ¹× ¿¬·É´ë±Ý±â ±Ù°ÅÁ¶È¸]
º¸°ü»ó ÁÖÀÇ
Á¶Á¦½Ã ÁÖÀÇ
½É»çÁ¤º¸
ÇмúÁ¤º¸
Ç׸ñ
³»¿ë
DUR (ÀǾàǰ»ç¿ëÆò°¡)
º´¿ë±Ý±â :
°í½ÃµÈ º´¿ë±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[»óÈ£ÀÛ¿ë/º´¿ë±Ý±â°Ë»ö]
¿¬·É´ë±Ý±â :
°í½ÃµÈ ¿¬·É±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[¿¬·É´ë±Ý±â»ó¼¼°Ë»ö]
Mechanism of Action
Ciclopirox¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ Unlike antifungals such as itraconazole and terbinafine, which affect sterol synthesis, ciclopirox is thought to act through the chelation of polyvalent metal cations, such as Fe3+ and Al3+ . These cations inhibit many enzymes, including cytochromes, thus disrupting cellular activities such as mitochondrial electron transport processes and energy production. Ciclopirox also appears to modify the plasma membrane of fungi, resulting in the disorganization of internal structures. The anti-inflammatory action of ciclopirox is most likely due to inhibition of 5-lipoxygenase and cyclooxygenase.
Pharmacology
Ciclopirox¿¡ ´ëÇÑ Pharmacology Á¤º¸ Ciclopirox is a broad-spectrum antifungal medication that also has antibacterial and anti-inflammatory properties. Its main mode of action is thought to be its high affinity for trivalent cations, which inhibit essential co-factors in enzymes. Ciclopirox exhibits either fungistatic or fungicidal activity in vitro against a broad spectrum of fungal organisms, such as dermatophytes, yeasts, dimorphic fungi, eumycetes, and actinomycetes. In addition to its broad spectrum of action, ciclopirox also exerts antibacterial activity against many Gram-positive and Gram-negative bacteria. Furthermore, the anti-inflammatory effects of ciclopirox have been demonstrated in human polymorphonuclear cells, where ciclopirox has inhibited the synthesis of prostaglandin and leukotriene. Ciclopirox can also exhibit its anti-inflammatory effects by inhibiting the formation of 5-lipoxygenase and cyclooxygenase.
Absorption
Ciclopirox¿¡ ´ëÇÑ Absorption Á¤º¸ Rapidly absorbed after oral administration. Mean absorption of ciclopirox after application to nails of all twenty digits and adjacent 5 millimeters of skin once daily for 6 months in patients with dermatophytic onychomycoses was less than 5% of the applied dose. Ciclopirox olamine also penetrates into hair and through the epidermis and hair follicles into sebaceous glands and dermis.
Pharmacokinetics
Ciclopirox OlamineÀÇ ¾à¹°µ¿·ÂÇÐÀÚ·á
Èí¼ö : ¿Ü¿ë : Á¤»ó ÇǺΠ: 2% ¹Ì¸¸
´Ü¹é°áÇÕ : 94-98%
¹Ý°¨±â : 1.7½Ã°£
¼Ò½Ç : Èí¼öµÈ ¼Ò·®ÀÇ ¾à¹°Àº ÁÖ·Î ½Å¹è¼³µÇ°í, ¼Ò·®ÀÌ º¯¹è¼³µÈ´Ù.
Toxicity
Ciclopirox¿¡ ´ëÇÑ Toxicity Á¤º¸ Oral LD50 in rat is >10 ml/kg. Symptoms of overexposure include drowsiness and headache.
Drug Interactions
Ciclopirox¿¡ ´ëÇÑ Drug_Interactions Á¤º¸ Not Available
CYP450 Drug Interaction
[CYP450 TableÁ÷Á¢Á¶È¸]
Drug Target
[Drug Target]
Description
Ciclopirox¿¡ ´ëÇÑ Description Á¤º¸ Ciclopirox (also called Loprox®, Penlac® and Stieprox®) is a synthetic antifungal agent for topical dermatologic use. [Wikipedia]
Drug Category
Ciclopirox¿¡ ´ëÇÑ Drug_Category Á¤º¸ Antifungal Agents
Smiles String Canonical
Ciclopirox¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ CC1=CC(=O)N(O)C(=C1)C1CCCCC1
Smiles String Isomeric
Ciclopirox¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ CC1=CC(=O)N(O)C(=C1)C1CCCCC1
InChI Identifier
Ciclopirox¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/C12H17NO2/c1-9-7-11(13(15)12(14)8-9)10-5-3-2-4-6-10/h7-8,10,15H,2-6H2,1H3
Chemical IUPAC Name
Ciclopirox¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ 6-cyclohexyl-1-hydroxy-4-methylpyridin-2-one
»ç¿ëÀÚÄÁÅÙÃ÷
ÃÖ±ÙÁ¤º¸¼öÁ¤ÀÏ 2021-12-09
º» ¼öÁ¤ÀÏ Á¤º¸´Â Çã°¡Á¤º¸ ÀÌ¿ÜÀÇ ±âŸÁ¤º¸ ¼öÁ¤ÀÏÀ» ÀǹÌÇϹǷÎ, Çã°¡Á¤º¸¼öÁ¤ÀÏÀº º»¹®¿¡ Ç¥±âµÈ ³¯Â¥¸¦ ÂüÁ¶ÇϽñ⠹ٶø´Ï´Ù.
¾Ë¸²
»ó¼¼Á¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×À» Åä´ë·Î ÀÛ¼ºµÇ¾úÀ¸¸ç ¿ä¾àÁ¤º¸´Â »ó¼¼Á¤º¸ ¹× ±âŸ¹®ÇåÀ» ±â¹ÝÀ¸·Î µå·°ÀÎÆ÷¿¡¼ ÆíÁýÇÑ ³»¿ëÀÔ´Ï´Ù. Á¦Ç°Çã°¡»çÇ×ÀÇ ¸ñÂ÷¿Í ´Ù¼Ò »óÀÌÇÒ ¼ö ÀÖ½À´Ï´Ù.
°æ°í
µå·°ÀÎÆ÷ ÀǾàÇмúÁ¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×, Çмú¹®Çå, Á¦¾àȸ»ç Á¦°øÁ¤º¸ µîÀ» ±Ù°Å·Î ÀÛ¼ºµÈ Âü°í Á¤º¸ÀÔ´Ï´Ù.
Á¤º¸ÀÇ Á¤È®¼ºÀ» À§ÇØ ³ë·ÂÇϰí ÀÖÀ¸³ª ÆíÁý»óÀÇ ¿À·ù, Çã°¡»çÇ× º¯°æ, Ãß°¡ÀûÀÎ Çмú¿¬±¸ ¶Ç´Â Àӻ󿬱¸ ¹ßÇ¥ µîÀ¸·Î ÀÎÇØ ¹ß»ýÇÏ´Â ¹®Á¦¿¡ ´ëÇØ µå·°ÀÎÆ÷´Â
Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù. ÀÚ¼¼ÇÑ ³»¿ëÀº ¡°Ã¥ÀÓÀÇ ÇÑ°è ¹× ¹ýÀû°íÁö¡± ¸¦ ÂüÁ¶ÇØ ÁֽʽÿÀ.
¹Ýµå½Ã Á¦Á¶¡¤¼öÀÔ»ç, ÆÇ¸Å»ç, ÀÇ»ç, ¾à»ç¿¡°Ô ÃÖÁ¾ÀûÀ¸·Î È®ÀÎÇϽñ⠹ٶø´Ï´Ù.
ÀüÈ: 02-3486-1061 ¤Ó À̸ÞÀÏ: webmaster@druginfo.co.kr
¾Æ·¡ÀÇ ³»¿ëÀ» Æ÷ÇÔÇÑ Àüü µ¥ÀÌÅ͸¦ º¸½Ã·Á¸é
¿©±â ·Î À̵¿ÇϽñ⠹ٶø´Ï´Ù.
º´¿ë±Ý±â ¹× ƯÁ¤¿¬·É´ë ±Ý±â ¼ººÐ
[ÀǾàǰº´¿ë/¿¬·É´ë±Ý±â °í½Ã±Ù°Å·Î ¹Ù·Î°¡±â] Á¦¸ñ ¾øÀ½
2008³â 8¿ù 1ÀÏ ¾à°¡ÈÀÏ»ó 8¿ù´Þ ½Å±ÔµîÀç ¹× »èÁ¦µÇ´Â ǰ¸ñ Æ÷ÇÔÇÑ º´¿ë¿¬·É ±Ý±â ǰ¸ñ¸®½ºÆ® ±âÁØ
1. ÇöÀç °Ë»öÇÑ Á¦Ç°¿¡ ´ëÇÑ º´¿ë±Ý±â Á¦Ç° Á¸Àç¿©ºÎ ¹× °Ë»ö
ÇöÀç ÀÌÁ¦Ç°¿¡ ´ëÇÑ º´¿ë±Ý±â¿¡ ÇØ´çÇϴ û±¸Äڵ庰 Á¦Ç°³»¿ª °øÁö³»¿ëÀÌ ¾ø½À´Ï´Ù
2. ¿¬·É´ë±Ý±â Á¸Àç¿©ºÎ
ÇöÀç ÀÌÁ¦Ç°¿¡ ´ëÇÑ ¿¬·É±Ý±â¿¡ ÇØ´çÇϴ û±¸Äڵ庰 °øÁö³»¿ëÀÌ ¾ø½À´Ï´Ù